In human patients, dysregulated afadin expression has been associated with carcinogenesis and cancer metastasis in multiple tissue contexts, and somatic afadin loss-of-function mutations have recently been reported to drive a class of E-cadherin–positive metastatic breast cancer (25). This evidence concerns the gene AFDN and breast cancer.